SCHEMBL7059620

SCHEMBL7059620

OC[C@@H]1C[C@@H](O)[C@H](n2cnc3c(Cl)ncnc32)O1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 4/20 0.55
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
TYMP P19971 1/20 0.46
ADORA3 P0DMS8 4/20 0.46
DPP4 P27487 1/20 0.46
MEN1 O00255 1/20 0.46
SLC28A1 O00337 1/20 0.46
MAP3K7 O43318 1/20 0.46
SLC28A2 O43868 1/20 0.46
GAPDH P04406 1/20 0.46
MAPK1 P28482 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA2B P29275 1/20 0.46
ADORA1 P30542 1/20 0.46
STAT6 P42226 1/20 0.46
PI4KA P42356 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24538657 1.00 SLC29A1 (0.55) SLC29A1PDE4APDE4BPDE4CPDE4D
SCHEMBL3168059 0.87 EGFR (0.45) SLC29A1PDE4APDE4BPDE4CPDE4D
SCHEMBL19344399 0.87 TYMP (0.45) SLC29A1PDE4APDE4BPDE4CPDE4D
SCHEMBL3168049 0.87 EGFR (0.45) SLC29A1PDE4APDE4BPDE4CPDE4D
SCHEMBL12386194 0.87 TYMP (0.45) SLC29A1PDE4APDE4BPDE4CPDE4D
SCHEMBL98801 0.86 SLC29A1 (0.56) SLC29A1ADORA3DPP4MEN1SLC28A1
SCHEMBL98800 0.86 SLC29A1 (0.56) SLC29A1ADORA3DPP4MEN1SLC28A1
Cordycepin SCHEMBL21562220 0.85 ADORA3 (0.63) SLC29A1ADORA3DPP4MEN1SLC28A1
Cordycepin SCHEMBL23735980 0.85 ADORA3 (0.63) SLC29A1ADORA3DPP4MEN1SLC28A1
Cordycepin SCHEMBL21591024 0.85 ADORA3 (0.63) SLC29A1ADORA3DPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030204080-A1 Methods for producing nucleoside derivatives and intermediates therefor AJINOMOTO CO. INC (JP) 2003-10-30 US disclosed
US-20030004330-A1 Methods for producing nucleoside derivatives and intermediates therefor AJINOMOTO CO. INC (JP) 2003-01-02 US disclosed
US-6500946-B1 LOW COST, SIMPLE, HIGH YIELD PRODUCTION, INCLUDING THAT OF ANTIVIRAL AGENT 9-(2,3-DIDEOXY-2-FLUORO-.BETA.-D-THREO-PENTOFURANOSYL)ADENINE (FDDA) AJINOMOTO CO., INC. (JP) 2002-12-31 US disclosed
US-6090937-A Methods for producing nucleoside derivatives and intermediates therefor AJINOMOTO CO., INC. (JP) 2000-07-18 US disclosed
EP-0945460-A1 Methods for producing nucleoside derivatives and intermediates therefore Ajinomoto Co., Inc. (JP) 1999-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004330-A1 Methods for producing nucleoside derivatives and intermediates therefor DCTD, ADAR, IMPDH1 SLC29A1 26/4885PDE4A 1063/4885PDE4B 656/4885
US-20030204080-A1 Methods for producing nucleoside derivatives and intermediates therefor DCTD, ADAR, IMPDH1 SLC29A1 26/4885PDE4A 1063/4885PDE4B 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.